Skip to main content
OpenTrials
Completed

NCT Number: NCT04311099

Optimal Peripheral Nerve Block After Minimally Invasive Colon Surgery

The purpose of the trial is to identify the "most simple non-inferior of three different methods", placebo, laparoscopic assisted transverse abdominal plane block (L-TAP) and ultrasound guided TAP block (US-TAP), using postoperative opioid consumption as a measure of efficacy in patients undergoing elective minimally invasive colon surgery in an ERAS setting. Postoperative pain scores and length of stay (LOS) will also be measured. The simplicity of the three methods is ranked as: 1) placebo, 2) L-TAP and 3) US-TAP.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Introducing laparoscopy in colorectal surgery and optimizing the postoperative care using the standardized protocols of enhanced recovery after surgery (ERAS) have significantly improved patient outcomes and LOS. Better pain management has the potential to further improve these outcomes. Since the introduction of ultrasound-guided abdominal wall blocks, much research has been done in that field, but no consensus has been reached concerning the optimal block technique; where to and when to inject the block, or which drug to use. Newly published randomized controlled trials show interesting results regarding the L-TAP which has several advantages to the US-TAP, including the ease of performance, less dependency on specialized skills or equipment and avoidance of intraperitoneal infiltration. but these results need to be solidified with multicentre trials. Besides optimizing postoperative pain management, better block techniques could potentially decrease LOS in patients after minimally invasive colorectal surgery.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients planned to receive curative elective minimally invasive colon surgery for colon cancer or adenoma without a planned ostomy. Colon cancer or adenoma is defined by a distance of more than 15 cm from the anal verge to the distal limitation of the tumour or adenoma as measured by rigid sigmoidoscope. The following procedural codes are included:
  • Laparoscopic ileocecal resection
  • Laparoscopic right hemicolectomy
  • Other laparoscopic resection of both small and large bowel
  • Laparoscopic resection of transverse colon
  • Laparoscopic left hemicolectomy
  • Laparoscopic resection of sigmoid colon
  • Other laparoscopic colon resection
  • Having given informed written consent.

Exclusion criteria

  • Known allergy to local analgesics
  • Known liver failure Class C according to the Child-Pugh Score
  • Body weight of less than 40 kg
  • History of being a chronic pain patient (weekly intake WHO step II or step III or adjuvant step I analgesic)
  • Presence of concomitant painful conditions other than low back pain that could confound the subject's trial assessments or self-evaluation of the index pain, e.g., syndromes with widespread pain such as fibromyalgia
  • Predictably non-compliant due to language barrier or psychiatric disease
  • Patients rescheduled for open surgery, before the intervention has been administered
  • Patients where the indication for surgery changes before the intervention has been administered
  • Patients with known inflammatory bowel disease
  • Patients who have previously undergone open major abdominal surgery defined by prior intraabdominal surgery with a midline or upper abdominal incision of more than 8 cm
  • Incisional hernia
  • Patients with a history of abdominal wall surgery including resection of the external oblique muscles, the internal oblique muscles, the transversus abdominis muscles, the rectus abdominis muscles or their fascial components
  • Pregnancy (patients are screened using urine human chorionic gonadotropin upon admission if female and not postmenopausal).

Treatment and study plan

Active drug

Drug

Injection of Ropivacaine

Other names: Ropivacaine

Placebo

Drug

Injection of Saline solution

Other names: Saline solution

Injection of Ropivacaine - Ultrasound-guided transverse abdominal plane block

Procedure

Lateral ultrasound-guided transverse abdominal plane block 40 ml ropivacaine 2 mg / ml

Injection of Ropivacaine - Laparoscopic assisted transverse abdominal plane block

Procedure

Laparoscopic assisted subcostal transverse abdominal plane block 40 ml ropivacaine 2 mg / ml

Injection of placebo - Ultrasound-guided transverse abdominal plane block

Procedure

Lateral ultrasound-guided transverse abdominal plane block with saline solution

Injection of placebo - Laparoscopic assisted transverse abdominal plane block

Procedure

Laparoscopic assisted subcostal transverse abdominal plane block with saline solution

Primary outcomes

  1. Total morphine dose equivalents administered.

    Time frame: The first 24 hours from the end of anesthesia.

    Intravenously in milligrams.

Secondary outcomes

  1. Total morphine dose equivalents administered in the operation theater.

    Time frame: Up to 12 hours.

    Intravenously in milligrams.

  2. Total morphine dose equivalents administered in the post anesthesia care unit.

    Time frame: The first 24 hours from the end of anesthesia.

    Intravenously in milligrams.

  3. Postoperative pain at rest - 8:00-10:00 AM (ante meridiem) Postoperative Day 1.

    Time frame: Postoperative Day 1.

    11-point Numeric Rating Scale. 0-10 (higher score - worse outcome).

  4. Postoperative pain when coughing - 8:00-10:00 AM Postoperative Day 1

    Time frame: Postoperative Day 1.

    11-point Numeric Rating Scale. 0-10 (higher score means worse outcome)

  5. Postoperative length of stay.

    Time frame: Up to 30 days.

    Days - Measured from the end of anesthesia.

  6. Incidence of Postoperative Nausea and Vomiting - 8:00-10:00 AM Postoperative Day 1.

    Time frame: Postoperative Day 1.

    4-point Numeric Rating Scale. 0-3 (higher score means worse outcome).

  7. Total dose of antiemetic medication administered.

    Time frame: In the first 24 hours from the end of anesthesia.

    Intravenously in milligrams.

  8. Total dose of antiemetic medication administered in the operating theater.

    Time frame: Up to 12 hours.

    Intravenously in milligrams.

  9. Time spent in the post anesthesia care unit.

    Time frame: Up to 30 hours.

    From the end of anesthesia to discharge to ward. Measured in hours and minutes.

  10. Postoperative mobilisation.

    Time frame: Postoperative Day 1.

    4-point Verbal Rating Scale. 1-4 (higher score means worse outcome).

  11. Quality of Recovery 15.

    Time frame: Postoperative Day 1.

    The Quality of Recovery 15 is a 15-item questionnaire that measures the patient's quality of recovery. Each item is answered on an 11-point Numerical Rating Scale. The score ranges from 0 to 150 with a higher score indicating a better quality of recovery. It measures in the domains of pain, physical comfort, physical independence, psychological support, and emotional state.

  12. Postoperative complications.

    Time frame: Postoperative Day 30.

    According to the Clavien-Dindo classification of surgical complications.

  13. Need for rescue TAP-block or epidural analgesia.

    Time frame: Postoperative Day 30.

    Epidural or TAP-block administered post surgery.

Sponsors and collaborators

Lead sponsor

Claus Anders Bertelsen, PhD, MD

Other

Registry information

Official study title

Laparoscopic vs Ultrasound-Guided Transversus Abdominis Plane Block in Minimally Invasive Colon Surgery: A Randomized Controlled Multicentre Clinical Trial

Acronym: OPMICS

Important dates

Study start
2021
Primary completion
2024
Study completion
2024
First posted
Mar 17, 2020
Registry last updated
Aug 7, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.